Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smartphone platform give ICU teams a head start on danger?

NCT ID NCT07773675

Disease control Sponsor: Sohag University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This trial tests whether an integrated mobile health platform can help detect clinical problems earlier in critically ill patients. The platform automatically collects and analyzes vital signs and lab trends from ICU monitors, generating real-time alerts for healthcare providers. Researchers will compare outcomes like ICU death rates, length of stay, and complications between patients monitored with the platform and those receiving standard care. The goal is to see if this digital tool can improve early detection and ultimately save lives.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
An integrated mobile health platform that automatically collects and analyzes vital signs and lab trends in the ICU, generating early warning alerts for healthcare providers.
What this could lead to
If it works, this digital tool could help ICU teams spot dangerous changes earlier, potentially reducing deaths and shortening hospital stays for critically ill patients.
What could go wrong
This is an early-stage study, and the platform's benefits are not yet proven. It may not reliably improve outcomes, and technical issues or alert fatigue could limit its real-world impact.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult patients aged 18-65 years. 2. Anticipated ICU stay of more than 24 hours. 3. Clinical requirement and ability to continuously monitor vital signs and urine output. 4. Obtained written informed consent from the patient or their legal guardians. Exclusion Criteria: 1. Patients placed in strict isolation due to highly infectious diseases. 2. Death within 24 hours of ICU admission. 3. Patients transferred from another external Intensive Care Unit. 4. Re-admission to the ICU during the active study period. 5. Pre-existing chronic altered consciousness or irreversible neurological deficit. 6. Patients who underwent pre-hospital cardiopulmonary resuscitation (CPR).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Clinical outcomes are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Clinical outcomes Mobile health platform

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Sohag University Hospital, General Intensive Care Unit

    Sohag, Sohag Governorate, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.